Compare Micron Technology, Inc. (MU) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Micron Technology, Inc. vs Neurocrine Biosciences Inc — how do they compare? Micron Technology, Inc. trades at $1,027.08 (market cap $1.13T), while Neurocrine Biosciences Inc trades at $155 (market cap $15.77B). The key difference: Micron Technology, Inc. is far larger — about 71.7× Neurocrine Biosciences Inc's market cap, and Micron Technology, Inc. pays a 0.05% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| MU | NBIX | |
|---|---|---|
Market Cap | $1.13T | $15.77B |
Sector | Technology | Health |
52-Week High | $1.21K | $185.50 |
52-Week Low | $140.00 | $123.10 |
Enterprise Value | $1.11T | $15.78B |
Dividend Yield | 0.05% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Micron Technology (MU) trades at $1,000.26, down 1.61% on the day, but remains in a bullish technical trend with strong analyst support. The stock has consistently beaten earnings estimates, with Q1 2026 EPS of $25.11 surpassing the $20.98 forecast. Fundamentals show robust growth, with 2025 revenue at $37.38 billion and net income margin of 55.91%. Positive sentiment is driven by AI-driven memory demand and projected 2026 revenue of $90.3 billion.
Outlook is bullish given memory supply constraints and AI tailwinds, but risks include cyclical industry volatility and high valuation multiples. The consensus price target is $1,540 with 82.9% of analysts rating it a buy. Investors should weigh strong cash flow growth against potential margin pressures if demand softens.
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Micron Technology, Inc.
Micron historically focused on designing and manufacturing DRAM for PCs. The firm then expanded into the NAND flash memory market. It increased its DRAM scale with the purchase of Elpida (completed in mid-2013) and Inotera (completed in December 2016). The firm's DRAM and NAND products tailored to PCs, data centers, smartphones, game consoles, automotives, and other computing devices.
Read more on MU →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
